Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
AstraZeneca's $1.3B bet yields 2nd phase 3 blood pressure win
The phase 3 win for baxdrostat boost AstraZeneca's attempts to turn the molecule’s long half-life into a competitive advantage.
Nick Paul Taylor
Oct 7, 2025 4:01am
Opus sets sights on FDA talks after posting gene therapy data
Sep 30, 2025 9:15am
Pfizer’s new prize Metsera touts 14% weight loss for GLP-1
Sep 30, 2025 6:40am
Enanta sees RSV drug fail phase 2b but finds positives
Sep 29, 2025 8:05am
MoonLake stock sinks as high placebo rate eclipses ph. 3 results
Sep 29, 2025 8:05am
Harmony's pivotal trial flops as placebo response causes discord
Sep 24, 2025 9:35am
